about
Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens.Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategiesInnate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo.Distinctive Responses in an In Vitro Human Dendritic Cell-Based System upon Stimulation with Different Influenza Vaccine Formulations.Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation.A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease.Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.Monophosphoryl lipid A-adjuvanted virosomes with Ni-chelating lipids for attachment of conserved viral proteins as cross-protective influenza vaccine.Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus.Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza VaccinesCross-protective immune responses induced by sequential influenza virus infection and by sequential vaccination with inactivated influenza vaccinesCross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of ImmunizationThe effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity
P50
Q30353863-6F9DFFD8-E97D-4109-9CA1-A149218A72F2Q33964519-FC40F3C9-3E71-403B-8AE8-568356A28441Q34533085-F1900515-C97C-4A1E-AC2E-FA7224050BF5Q34920723-1AC2577A-03DC-433B-A24C-08D6771CE98CQ35560781-5B4CE7BF-2556-45CC-A7AF-2190876E814CQ38695329-DDD73FC9-F094-4822-939B-EA22FA9E6FC4Q40106084-BC87057C-5055-4A64-A770-72D00CEE1EC9Q40169196-16C4095C-2B1A-4FA2-8EC0-C863DFC17D83Q40470546-41F0C0B7-F02F-4175-B67F-6932EABF34D4Q41303834-BAE0EBF6-17A9-4488-A610-EF71D2E187C7Q45421625-E22E280E-1D6B-47BE-A13D-341B5B2BDBA5Q47254369-6A399B7C-594F-4DCB-AE08-69F2D216A083Q49943194-123A73D5-5086-49D7-AF12-E366A9A0A717Q57816687-D9F42493-F143-4DBD-8478-587A573D987FQ58382353-D79E428F-B8C4-43C7-8018-7D3CA64B0B96Q64102134-CFA8FA63-32E1-41BD-B3E9-EB5669C1A145Q81050003-0CC0AB69-BCF3-46BA-9060-E6F1F68E342A
P50
name
Jacqueline de Vries-Idema
@en
type
label
Jacqueline de Vries-Idema
@en
prefLabel
Jacqueline de Vries-Idema
@en